Ovarian clear cell carcinoma (OCCC) is the most lethal gynecological cancer. It is characterized by somatic inactivating mutations of ARID1A, a component of the SWI/SNF chromatin-remodeling complex, occurring in up to 70% of patients. Patients with these mutations in their tumors have considerably p...
Evaluation of the efficiency and reproducibility of sample prepration methods using iST-BCT kit from PreOmics or SMART Trypsin Kit (Thermo Fisher) with in-house Rapigest protocol in human serum samples prior to mass spectrometry analysis.
- Within ovarian cancer research, patient-derived xenograft (PDX) models recapitulate histologic features and genomic aberrations found in original tumors. However, conflicting data from published studies have demonstrated significant transcriptional differences between PDXs and original tumors, whi...
Compare protein and peptide identification, technical reproducibility, proteome depth, dynamic range, and gene ontology enrichment of ascites fluid. Enrichment will selectively isolate low abundance proteins and exclude high abundance proteins, enhancing depth of proteomic coverage.
Compare protein and peptide identification, technical reproducibility, proteome depth, dynamic range, and gene ontology enrichment of ascites fluid. Enrichment will selectively isolate low abundance proteins and exclude high abundance proteins, enhancing depth of proteomic coverage.
High-grade serous ovarian cancer (HGSOC) is the deadliest gynecologic malignancy in women.The lack of effective second line therapeutics remains a substantial challenge for BRCA-1/2 wildtype HGSOC patients, and contributes to poor survival rates due to drug resistance. There is a striking need to el...
To detect the off-target effects of PARP inhibition, a quantitative mass spectrometry-based proteomic analysis was conducted of a BRCA1-mutated HGSOC cell line treated with low doses of two PARPi, Niraparib and Rucaparib.
this project carried out a global mass spectrometry analysis in a panel of HGSOC cell lines analyzing proteomic perturbations following HDACi treatment